KYMERA THERAPEUTICS INC

Kymera Therapeutics insider sale: Bruce Booth sells 7,833 shares at $109.75 under a 10b5‑1 plan, amid a 16.7% weekly rally and bullish analyst outlook.

BVF Partners sells 837,914 Kymera shares at $106.50— a tactical rebalancing amid broader insider selling, not a bearish signal for Kymera’s biotech pipeline.

Kymera insiders sell 1,235 shares under a 10b5‑1 plan, signaling liquidity moves amid governance changes—investors should watch future filings.

BVF Partners’ latest Kymera buy signals confidence in its clinical pipeline and governance overhaul—an insider‑driven hint at future upside.

Insider trading insight: Goodman Noah’s June 25 buys and sells show a disciplined 10b5‑1 strategy, signaling confidence in Kymera’s future upside.

Kymera insider activity: CEO‑level NSO grant signals bullish confidence in the company’s pipeline and long‑term upside potential for investors.

Kymera CFO Bruce Jacobs buys 12,653 shares, signaling strong confidence in the company’s clinical pipeline and long‑term upside—investors see a potential rebound.

Kymera Therapeutics COO Jeremy G. Chadwick’s recent insider sales reveal routine tax‑withholding trades, not a strategic move, keeping investor confidence high.

Kymera insiders buying shares at discount and selling options at market shows confidence, hinting at future growth amid volatile biotech market.

Kymera CFO buys 15k shares and sells options—insider confidence and risk‑mitigation signal. Learn what this means for the biotech stock’s future.